Engineering enhancement of immune responses to DNA-based vaccines in a prostate cancer model in rhesus macaques through the use of cytokine gene adjuvants

Clinical Cancer Research

Volumn 7, Issue 11 SUPPL., 2001, Pages

  Kim, J Joseph ^a,c   Yang, Joo Sung ^a   Dang, Kesen ^a   Manson, Kelledy H ^b   Weiner, David B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Primedica Mason Laboratories   (United States)

^c VGX Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; COMPLEMENTARY DNA; CYTOKINE; DNA VACCINE; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; PROSTATE SPECIFIC ANTIGEN;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BIOLOGICAL MODEL; CELL DIVISION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; LYMPHOCYTE; MACACA; MALE; METABOLISM; MOUSE; PROSTATE TUMOR; T LYMPHOCYTE; TIME;

ANIMALS; CANCER VACCINES; CELL DIVISION; CYTOKINES; DNA, COMPLEMENTARY; ENZYME-LINKED IMMUNOSORBENT ASSAY; INTERLEUKIN-12; INTERLEUKIN-18; INTERLEUKIN-2; LYMPHOCYTES; MACACA MULATTA; MALE; MICE; MICE, INBRED BALB C; MODELS, BIOLOGICAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; T-LYMPHOCYTES; TIME FACTORS; VACCINES, DNA;

EID: 0035293325     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Boring, C. C., Squires, T. S., and Tong, T. Cancer statistics. CA Cancer J. Clin., 44: 7-26, 1994.
2. Garnick, M. B., and Fair, W. R. Combating prostate cancer. Sci. Am., 274: 74-83, 1998.
3. O'Donnell, P. D., and Finan, B. F. Continence following nerve-sparing radical prostatectomy. J. Urol., 142: 1227-1229, 1989.
4. Zagars, G. K., and Pollack, A. Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome. Urology, 45: 476-483, 1995.
5. D'Amico, A. V., Whittington, R.,. Kaplan, I., Beard, C., Schultz, D., Malkowicz, S. B., Wein, A., Tomaszewski, J. E., and Coleman, C. N. Calculated prostate carcinoma volume: the optimal predictor of 3-year prostate specific antigen (PSA) failure free survival after surgery or radiation therapy of patients with pretreatment PSA levels of 4-20 nanograms per milliliter. Cancer (Phila.), 82: 334-341, 1998.
6. Wang, M. C., Kuriyama, M., Papsidero, L. D., Loor, R. M., Valenzyela, L. A., Murphy, G. P., and Chu, T. M. Prostate antigen of human cancer patients. Methods Cancer Res., 19: 179-197, 1982.
7. Watt, K. W. K., Lee, P-J., M'Timkulu, T., Chan, W-P., and Loor, R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc. Natl. Acad. Sci. USA, 83: 3166-3170, 1986.
8. Labrie, F., DuPont, A., Suburu, R., Cusan, L., Tremblay, M., Gomez, J. L., and Edmond, J. Serum prostate specific antigen as a pre-screening test for prostate cancer. J. Urol., 151: 1283-1290, 1992.
9. Godley, P. A. Prostate cancer screening: promise and peril-a review. Cancer Detect. Prev., 23: 316-324, 1999.
10. Armbruster, D. A. Prostate-specific antigen: biochemistry, analytical methods, and clinical applications. Clin. Chem., 39: 181-195, 1993.
11. Hodge, J. W., Schlom, J., Donohue, S. J., Tomaszewski, J. E., Wheeler, C. W., Levine, B. S., Gritz, L., Panicali, S., and Kantor, J. A. A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate. Int. J. Cancer, 63: 231-237, 1995.
12. Kim, J. J., Trivedi, N. N., Wilson, D. M., Mahalingam, S., Morrison, L., Tsai, A., Chattergoon, M. A., Dang, K., Patel, M., Ahn, L., Chalian, A. A., Boyer, J. D., Kieber-Emmons, T., Agadjanyan, M. G., and Weiner, D. B. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine. Oncogene, 17: 3125-3135, 1998.
13. Kim, J. J., and Weiner, D. B. DNA/genetic vaccination for HIV. Springer Semin. Immunopathol., 19: 174-195, 1997.
14. Kim, J. J., Bagarazzi, M. L., Trivedi, N., Hu, Y., Chattergoon, M. A., Dang, K., Mahalingam, S., Agadjanyan, M. G., Boyer, J. D., Wang, B., and Weiner, D. B. Engineering of in vivo immune responses to DNA immunization via co-delivery of costimulatory molecule genes. Nat. Biotechnol., 15: 641-645, 1997.
15. Kim, J. J., Ayyvoo, V., Bagarazzi, M. L., Chattergoon, M. A., Dang, K., Wang, B., Boyer, J. D., and Weiner, D. B. In vivo engineering of a cellular immune response by co-administration of IL-12 expression vector with a DNA immunogen. J. Immunol., 158: 816-826, 1997.
16. Kim, J. J., Trivedi, N. N., Nottingham, L., Morrison, L., Tsai, A., Hu, Y., Mahalingam, S., Dang, K., Ahn, L., Doyle, N. K., Wilson, D. M., Chattergoon, M. A., Chalian, A. A., Boyer, J. D., Agadjanyan, M. G., and Weiner, D. B. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. Eur. J. Immunol., 28: 1089-1103, 1998.
17. Sin, J. I., Kim, J. J., Boyer, J. D., Huggins, C., Higgins, T., and Weiner, D. B. In vivo modulation of immune responses and protective immunity against herpes simplex virus-2 infection using cDNAs expressing Th1 and Th2 type cytokines in gD DNA vaccination. J. Virol., 73: 501-509, 1998.
18. Kim, J. J., Yang, J-S., VanCott, T. C., Lee, D. J., Manson, K. H., Wyand, M. S., Boyer, J. D., Ugen, K. E., and Weiner, D. B. Modulation of antigen-specific humoral responses in rhesus macaques using cytokine cDNA as DNA vaccine adjuvants. J. Virol., 74: 3427-3429, 2000.
19. Jiao, S., Williams, P., Berg, R. K., Hodgeman, B. A., Liu, L., Repetto, G., and Wolff, J. A. Direct gene transfer into non-human primate myofibers in vivo. Hum. Gene Ther., 3: 21-33, 1992.
20. Small, E. J. Advances in prostate cancer. Curr. Opin. Oncol., 11: 226-235, 1999.
21. Vieweg, J., Boczkowski, D., Roberson, K. M., Edwards, D. W., Philip, M, Philip, R., Rudoll, T., Smith, C , Robertson, C., and Gilboa, E. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res., 54: 1760-1765, 1994.
22. Sandra, M. G. Demonstration of a rational strategy for human prostate cancer gene therapy. J. Urol., 151: 622-628, 1994.
23. Tjca, B., Boynton, A., Kenny, G., Ragde, H., Misrock, S. L., and Murphy, G. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate, 28: 65-69, 1996.
24. Murphy, G., Tjoa, B., Ragde, H., Kenny, G., and Boynton, A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen AU. Prostate, 29: 371-380, 1996.
25. Malkowicz, S. B., and Johnson, J. O. Gene therapy for prostate cancer. Hematol. Oncol. Clin. North Am., 12: 649-664, 1998.
26. MacGregor, R. R., Boyer, J. D., Ugen, K. E., Lacy, K., Gluckman, S., Bagarazzi, M. L., Chattergoon, M., Baine, Y., Higgins, T. J. Ciccarelli, R. B., Coney, L. R., Ginsberg, R. S., and Weiner, D. B. First human trial of a facilitated DNA plasmid vaccine for HIV-1: safety and host response. J. Infect. Dis., 178: 92-100, 1998.
27. Wang, R., Doolan, D. L., Le, T. P., Hedstrom, R. C., Coonan, K. M., Charoenvit, Y., Jones, T. R., Hobart, P., Margalith, M., Ng, J., Weiss, W. R., Sedegah, M., de Taisne, C., Norman, J. A., and Hoffman, S. L. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science (Washington DC), 282: 476-480, 1998.
28. Kelley, J. R., and Cole, D. J. Gene therapy strategies utilizing carcinoembryonic antigen as a tumor associated antigen for vaccination against solid malignancies. Gene Ther. Mol. Biol., 2: 14-30, 1998.
29. Stenman, U. H., Leinonen, J., Zhang, W. M., and Finne, P. Prostate-specific antigen. Semin. Cancer Biol., 2: 83-93, 1999.